Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

S&P 500 E-Mini futures (ESU25) are up +0.27%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.28% this morning, ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Wall Street awaits earnings Monday from Verizon.

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...